Europe Bacteriophages Therapy Market, By Target (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, and Others), Type (Lytic, and Lysogenic), Base (Sterile Broth Culture, and Water-Soluble Jelly Base), Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Other), Application (Bacterial Dysentery, Infections Of Skin And Nasal Mucosa, Suppurative Skin Infection, Lung and Pleural Infections, Postoperative Wound Infections, and Others), Route Of Administration (Oral, Parenteral, Rectal, Dermal, and Others), End-User (Hospitals, Speciality Clinics, Academic Research And Institutes, and Others), Distribution Channel (Direct Tender, and Third Party Distributors) – Industry Trends and Forecast to 2031.
Europe Bacteriophages Therapy Market Analysis and Size
The autoimmune disease diagnosis market is vital for identifying and managing conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. Utilized in clinical settings, these diagnostics enable early detection, precise disease monitoring, and improving patient outcomes and quality of life in autoimmune disease management.
Data Bridge Market Research analyses that the Europe bacteriophages therapy market, which was USD 15.31 million in 2023, is expected to reach USD 22.80 million by 2031, and is expected to undergo a CAGR of 5.1% during the forecast period of 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Target (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, and Others), Type (Lytic, and Lysogenic), Base (Sterile Broth Culture, and Water-Soluble Jelly Base), Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis, and Other), Application (Bacterial Dysentery, Infections Of Skin And Nasal Mucosa, Suppurative Skin Infection, Lung and Pleural Infections, Postoperative Wound Infections, and Others), Route Of Administration (Oral, Parenteral, Rectal, Dermal, and Others), End-User (Hospitals, Speciality Clinics, Academic Research And Institutes, and Others), Distribution Channel (Direct Tender, and Third Party Distributors)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Microgen (India), Micreos (Netherlands), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics, Inc. (U.S.), Armata pharmaceuticals Inc. (U.S.), LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Pherecydes Pharma (France), iNtRON Biotechnology, Inc. (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Eliava Biopreparation LLC (Georgia), Phagelux, Inc. (China), TechnoPhage (Portugal), Eligo Bioscience (France), BiomX Inc. (Israel)
|
|
Market Opportunities
|
|
Market Definition
Autoimmune disease diagnosis involves a comprehensive approach, combining medical history, physical examination, laboratory tests, and imaging studies. Common diagnostic tools include blood tests to detect autoantibodies and inflammation markers, imaging techniques such as MRI or ultrasound, and biopsy for tissue analysis, aiding in accurate identification and management of autoimmune conditions.
Europe Bacteriophages Therapy Market Dynamics
Drivers
- Rising Potential for Personalized Medicine for Treatment Effectiveness
Bacteriophage therapy offers personalized medicine potential by precisely targeting specific bacterial strains in individual patients. This tailored approach enhances treatment effectiveness, addressing unique infections. The specificity of bacteriophages minimizes collateral damage to beneficial bacteria, highlighting a promising avenue for personalized and efficient antibacterial interventions in healthcare.
- Increasing Prevalence of Chronic Diseases Creates Demand for Antibacterial Solutions
The rise in chronic diseases such as diabetes, cancer, and organ transplantation compromises immunity, heightening vulnerability to bacterial infections. This escalation underscores the demand for potent antibacterial solutions such as bacteriophage therapy, offering targeted treatment against resistant strains, thereby addressing a critical healthcare need in the face of increasing disease complexity.
Opportunities
- Increasing Research and Development Finds Innovative Treatment Methods
Growing interest and investment in bacteriophage-based therapies drive research, fostering discovery of new phase and innovative treatment methods. This surge fuels the development of targeted solutions against antibiotic-resistant bacteria, addressing critical gaps in infectious disease management and advancing the field of tailored medicine.
- Rising Applications in Agriculture Sector for Food Security
Bacteriophages exhibit versatile applications, transcending human medicine. In agriculture, they emerge as formidable allies, combating bacterial pathogens that afflict crops and livestock. This intervention fortifies agricultural productivity and contributes significantly to global food security. The expansive role of bacteriophages extends beyond therapy, impacting diverse sectors and enhancing the overall resilience of ecosystems.
Restraints/Challenges
- Storage and Delivery of Bacteriophages Impede Market Growth
The shortage for precise storage conditions and varied delivery methods for bacteriophages can impede market growth. Logistical challenges in ensuring efficacy during storage and administering treatment to diverse infection sites may increase costs and limit accessibility. Such complexities deter healthcare providers and patients from adopting bacteriophage therapy, hindering its market expansion and utilization
- Bacterial Resistance from Antibiotic Affect Long-Term Efficacy
Bacterial resistance to bacteriophages, akin to antibiotic challenges, threatens bacteriophage therapy's sustainability. Resistance development affect long-term efficacy, echoing antibiotic issues. This undermines confidence in bacteriophage treatments, posing significant concerns for their durability in combating bacterial infections, and consequently, the stability of the bacteriophage therapy market.
This Europe bacteriophages therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe bacteriophages therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In November 2021, Intralytix and AB Agri joined forces to explore bacteriophages' potential in animal feed, signaling an expansion of bacteriophages therapy applications beyond human health
- In August 2021, Carillon Miami Wellness Resort partnered with the biostation to launch a functional medicine practice at its spa. This collaboration signifies a growing interest in bacteriophages therapy within the wellness industry
- In June 2021, BioChimpharm expanded production capacity with EU and FAO support, focusing on bacteriophages as alternatives to antibiotics. This reflects a rising trend in utilizing bacteriophages therapy for combating antibiotic resistance
- In March 2020, Fixed-Phage Limited collaborated with Carus Animal Health to develop bacteriophages-based solutions. This partnership underscores the growing interest in leveraging bacteriophages therapy for addressing bacterial infections in animals, indicating market diversification
Europe Bacteriophages Therapy Market Scope
The Europe bacteriophages therapy market is segmented on the basis of target, type, base, disease indication, application, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Target
- Escherichia Coli
- Staphylococcus
- Streptococcus
- Pseudomonas
- Salmonella
- Others
Type
- Lytic
- Lysogenic
Base
- Sterile Broth Culture
- Water-Soluble Jelly Base
Disease Indication
- Urinary Tract Infections
- Chronic Otitis
- Dental Extraction
- Chronic Ulcerative Colitis
- Bone Infection
- Wound and Skin Infections
- Cystic Fibrosis
- Other
Application
- Bacterial Dysentery
- Infections of Skin and Nasal Mucosa
- Suppurative Skin Infection
- Lung and Pleural Infections
- Postoperative Wound Infections
- Others
Route of Administration
- Oral
- Parenteral
- Rectal
- Dermal
- Others
End-User
- Hospitals
- Speciality Clinics
- Academic Research and Institutes
- Others
Distribution Channel
- Direct Tender
- Third Party Distributors
Europe Bacteriophages Therapy Market Regional Analysis/Insights
The Europe bacteriophages therapy market is analysed and market size insights and trends are provided by country, target, type, base, disease indication, application, route of administration, end-user, and distribution channel as referenced above.
The countries covered in the Europe bacteriophages therapy market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Georgia is expected to dominate the bacteriophages therapy market, showing the highest growth rate. This is attributed to the immediate recovery and therapeutic effect offered by lytic bacteriophage treatments.
Russia is expected to dominate the bacteriophages therapy market in the lytic segment due to advancements in phage therapy. These innovations position Russia as a leader in utilizing bacteriophages for treating bacterial infections.
Belgium is expected to dominate the bacteriophages therapy market due to its rising investment in innovative research and development for novel drug products, positioning it as a leader in advancing bacteriophage-based treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Europe bacteriophages therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe bacteriophages therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe bacteriophages therapy market. The data is available for historic period 2016-2021.
Competitive Landscape and Europe Bacteriophages Therapy Market Share Analysis
The Europe bacteriophages therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe bacteriophages therapy market.
Some of the major players operating in the Europe bacteriophages therapy market are:
- Microgen (India)
- Micreos (Netherlands)
- ATCC (U.S.)
- Intralytix, Inc. (U.S.)
- Adaptive Phage Therapeutics, Inc. (U.S.)
- Armata pharmaceuticals Inc. (U.S.)
- LOCUS BIOSCIENCES, INC. (U.S.)
- Delmont Laboratories, Inc. (U.S.)
- Pherecydes Pharma (France)
- iNtRON Biotechnology, Inc. (U.S.)
- Fixed-Phage Limited (U.K.)
- Cytophage Technologies Inc. (Canada)
- Eliava Biopreparation LLC (Georgia)
- Phagelux, Inc. (China)
- TechnoPhage (Portugal)
- Eligo Bioscience (France)
- BiomX Inc. (Israel)
SKU-